Pyxis Oncology, Inc. (NasdaqGS: PYXS)
Health Care · Biotechnology · US
$2.03
-5.14% today · -41.2% 1Y
Pyxis Oncology, Inc. (NasdaqGS: PYXS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $242.50M and employs 56 people.
Over the last twelve months the share price has lost 41.2%, trading between 1.03 and 5.55.
Tweenvest scores Pyxis Oncology, Inc. across four factors: quality 37/100, value 70/100. Its strongest factor is value.
PYXS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $242.50M
- Revenue (TTM)
- $11.04M
- P/E
- —
- EPS
- -1.40
- Dividend yield
- —
- Beta (5Y)
- 1.38
- 52-week high
- $5.55
- 52-week low
- $1.03
- Avg volume (3M)
- —
- Shares outstanding
- 119.46M
- Employees
- 56
- Next earnings
- —
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
- ISIN
- US7473241013
- Founded
- 2018
- Listed since
- Oct 8, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Acepodia, Inc.TPEX: 6976 | $244.38M | NT$13.40 | +4.69% |
| Oryzon Genomics S.A.BME: ORY | $243.20M | €2.65 | +0.76% |
| Polaris GroupTWSE: 6550 | $242.78M | NT$16.70 | -0.30% |
| Greenwich LifeSciences, Inc.NasdaqCM: GLSI | $242.63M | $16.53 | -2.65% |
| SillaJen, Inc.KOSDAQ: A215600 | $241.16M | ₩2,340.00 | -0.85% |
| MacroGenics, Inc.NasdaqGS: MGNX | $238.24M | $3.74 | +5.35% |
| Keros Therapeutics, Inc.NasdaqGM: KROS | $236.93M | $11.95 | +5.19% |
| Sutro Biopharma, Inc.NasdaqGM: STRO | $236.61M | $14.27 | -7.04% |
Figures last refreshed Oct 11, 2026.